Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

Phase 2

• Conditions: Cervical Intraepithelial Neoplasia

• Registration Number: NCT02596243
• Lead Sponsor: Genexine, Inc.

Brief Summary

The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)

Detailed Description

Not provided

Study Timeline

• Study Start: 2015-08
• Study First Submitted: 2015-11-03
• Study First Submitted QC: 2015-11-03
• Study First Posted: 2015-11-04
• Status Verified: 2017-07
• Last Update Submitted: 2017-07-11
• Last Update Posted: 2017-07-12
• Primary Completion: 2018-03
• Study Completion: 2018-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 134

Inclusion Criteria

1. Female subjects age 18-60 years
2. Histologically confirmed HPV-16 or HPV-18 asspcoated CIN2, CIN 2/3 or CIN3 from tissue collected less than 10 weeks prior to Vaccination/EP #1 with overall lesion sizes less than 50% of the cervix area and no evidence of invasive cancer in any specimen;
3. Colposcopy is satisfactory based on visualization of the entire squamocolumnar junction and the upper limit of the entire aceto-white or suspected CIN disease area;
4. Healthy subjects as judged by the Investigator based on medical history, PE, and normal results for an ECG, CBC, Serum Chemistries, CPK and urinalysis done up to 4 weeks prior to enrolment;
5. For women who are not postmenopausal (at least 12 months of nontherapy- induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use a highly effective method of contraception during the treatment period and throughout Week 36 response evaluation visit.
6. Able and willing to comply with all study procedures and voluntarily signs informed consent form.

Exclusion Criteria

1. Unsatisfactory colposcopy defined as incomplete visualization of the entire squamocolumnar junction and the upper limit of the entire aceto-white or suspected CIN disease area;
2. Pregnancy or breastfeeding;
3. Immunosuppression including any concurrent condition requiring the continued use of systemic or topical steroids at or near the injection site [deltoid, upper arm] (excluding inhaled and eye drop-containing corticosteroids) or the use of immunosuppressive agents. All other corticosteroids must be discontinued > 4 weeks prior to Day 0 of study vaccine administration; autoimmune disorders, transplant recipients;
4. History of previous therapeutic HPV vaccination (individuals who have been immunized with licensed prophylactic HPV vaccines (e.g. Gardasil®, Cervarix®) are not excluded);
5. Positive serological test for hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or human immunodeficiency virus (HIV);
6. Administration of any blood product within 3 months of enrollment;
7. Administration of any licensed vaccine within 2 weeks of enrollment (4 weeks for measles vaccine);
8. Participation in a study with an investigational compound or device within 30 days prior to signing informed consent;
9. Cardiac pre-excitation syndromes (such as Wolff-Parkinson-White);
10. History of seizures (unless seizure free for 5 years);
11. Tattoos, scars, active lesions/rashes or any implantable leads within 3 cm of the intended site of vaccination/EP;
12. Any electronic medical implants (such as cardiac pacemaker);
13. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements;
14. A tendency for severe haemorrhage following acute trauma;
15. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infections disease) illness must not be enrolled into this study;
16. Any other conditions judged by the investigator that would limit the evaluation of a subject.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Number of participants with histopathological regression of cervical lesions to CIN1 or less	36 weeks	The number of participants with cervical lesions regress to CIN1 or less at the 36 week visit

Secondary Outcome Measures

Name	Time	Method
Number of participants with Clearance of HPV 16 or 18 in combination with histopathological regression of cervical lesions to CIN1 or less	36 weeks	The number of participants with clearance of HPV 16 or 18 in combination with histopathological regression of cervical lesions to CIN1 or less at the 36 week visit

Trial Locations

Locations (16)

East Tallinn Central Hospital; 🇪🇪 Tallinn, Estonia

North Estonia Medical Centre Foundation; 🇪🇪 Tallinn, Estonia

Tartu University Hospital; 🇪🇪 Tartu, Estonia

Inje University Busan Paik Hospital; 🇰🇷 Busan, Korea, Republic of

Keimyung University Dongsan Medical Center; 🇰🇷 Daegu, Korea, Republic of

Severance Hospital; 🇰🇷 Seoul, Korea, Republic of

Cheil General Hospital & Women's Healthcare Center; 🇰🇷 Seoul, Korea, Republic of

CHA Gangnam Medical Center; 🇰🇷 Seoul, Korea, Republic of

The Catholic University of Korea Seoul St. Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of

Hallym University Kangnam Sacred Heart Hospital; 🇰🇷 Seoul, Korea, Republic of

Scroll for more (6 remaining)